SITAVAC-3D MAX 1000

Description:
SITAVAC-3D MAX 1000 is an advanced triple combination therapy containing Sitagliptin (DPP-4 inhibitor), Metformin (biguanide, 1000 mg), and Dapagliflozin (SGLT2 inhibitor). It is specially formulated for patients with Type 2 Diabetes Mellitus (T2DM) who require multiple mechanisms of action to achieve optimal blood sugar control.

• Sitagliptin improves insulin release and reduces glucagon levels.

• Metformin 1000 mg lowers glucose production in the liver and improves insulin sensitivity.

• Dapagliflozin helps the kidneys eliminate excess glucose through urine, thereby reducing blood sugar and aiding in weight management.

This triple-action formula provides comprehensive glycemic control and reduces the risk of long-term complications of diabetes.

Key Benefits:

• Triple therapy for effective Type 2 Diabetes management

• Improves insulin sensitivity and reduces sugar production

• Promotes glucose elimination via kidneys

• Helps reduce HbA1c levels significantly

• Supports weight management in diabetic patients

• Low risk of hypoglycemia compared to insulin or sulfonylureas

• May provide cardiovascular and renal protection